Following the death of two teenage patients with Duchenne muscular dystrophy following Elevidys treatment, Sarepta ...

With venture funding tightening in the post-COVID landscape, efficiency has become more critical than ever. In this ...

Seven biotech unicorns are advancing AI-powered drug discovery and development—but must contend with a difficult investing ...

Johnson & Johnson kicked off Q2 2025 pharma earnings season with a bang Wednesday, adding $2 billion to the midpoint of its ...

In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...

Around 3,500 FDA employees received termination emails; FDA Commissioner Marty Makary suggests lowering industry user fees ...

From Wall Street to real estate to a “big, ugly” pharma building, Mayo Venture Partner Audrey Greenberg reflects on a career ...

The antibody anselamimab, which AstraZeneca picked up in its 2021 purchase of Caelum Biosciences, failed to improve survival and reduce hospitalizations, but the company sees promise in data from an ...

It’s easy to get caught up in defending yourself against critique that feels unfair. Leadership coach Angela Justice recommends a different approach that can help you better align how you want to be ...

Some of the most high-profile acquisitions in recent years have involved women-fronted biotechs. BioSpace reviews five of the most notable here.

Thousands of employees across HHS were terminated Monday evening after the U.S. Supreme Court ruled last week that the Trump ...

According to Makary, reducing user fees—which make up just under half of the FDA's budget—could make it easier for smaller ...